Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A look at Anthos Therapeutics' Abelacimab and the results of the AZALEA-TIMI 71 trial presented at the American Heart Association’s Scientific Sessions.

Ticker(s): ANTHOS THERAPEUTICS

Who's the expert?

Institution: University of Arizona

Professor of Medicine in the Department of Medicine and Medical Director of cardiac rehabilitation at the University of Arizona College of Medicine at Tucson
Treats 4-5 patients every week with atrial fibrillation at moderate-to-high risk of stroke
Areas of interest include acute ischemic heart disease, cardiovascular pharmacology, and cardiovascular epidemiology

Interview Goal

On this call we will discussing the potential of Anthos Therapeutics' Abelacimab, a dual-acting Factor XI / XIa Inhibitor, for as an alternative to direct oral anticoagulants for patients at moderate-to-high risk of stroke.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.